- Home
- GROW vs SCYX Comparison
GROW vs SCYX Comparison
Compare GROW & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROW
- SCYX
- Stock Information
- Founded
- GROW 1968
- SCYX 1999
- Country
- GROW United States
- SCYX United States
- Employees
- GROW N/A
- SCYX N/A
- Industry
- GROW Investment Managers
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- GROW Finance
- SCYX Health Care
- Exchange
- GROW Nasdaq
- SCYX Nasdaq
- Market Cap
- GROW 31.8M
- SCYX 28.5M
- IPO Year
- GROW N/A
- SCYX 2014
- Fundamental
- Price
- GROW $2.43
- SCYX $0.70
- Analyst Decision
- GROW
- SCYX
- Analyst Count
- GROW 0
- SCYX 0
- Target Price
- GROW N/A
- SCYX N/A
- AVG Volume (30 Days)
- GROW 46.1K
- SCYX 127.6K
- Earning Date
- GROW 05-08-2025
- SCYX 08-07-2025
- Dividend Yield
- GROW 3.73%
- SCYX N/A
- EPS Growth
- GROW N/A
- SCYX N/A
- EPS
- GROW 0.01
- SCYX N/A
- Revenue
- GROW $8,932,000.00
- SCYX $2,630,000.00
- Revenue This Year
- GROW N/A
- SCYX $463.61
- Revenue Next Year
- GROW N/A
- SCYX $310.80
- P/E Ratio
- GROW $233.35
- SCYX N/A
- Revenue Growth
- GROW N/A
- SCYX N/A
- 52 Week Low
- GROW $2.02
- SCYX $0.66
- 52 Week High
- GROW $2.73
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- GROW 54.60
- SCYX 40.46
- Support Level
- GROW $2.43
- SCYX $0.70
- Resistance Level
- GROW $2.49
- SCYX $0.75
- Average True Range (ATR)
- GROW 0.09
- SCYX 0.04
- MACD
- GROW -0.01
- SCYX 0.00
- Stochastic Oscillator
- GROW 38.53
- SCYX 32.29
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.